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Summary. We evaluated the ability of recombinant human
erythropoietin (rHuEpo) therapy, given before high-dose
therapy (HDT), to allow autologous peripheral blood stem
cell transplantation (PBSCT) without red blood cell (RBC)
transfusions. Eleven multiple myeloma patients underwent
tandem HDT and autologous PBSC, receiving 500 U/kg/
week rHuEpo from d 30 after initial transplant. Haemo-
globin levels were 9Æ5 ± 1Æ1 g/dl and 12Æ5 ± 0Æ9 g/dl at the
first and second transplant respectively (P < 0Æ001). RBC
transfusions were required for 10/11 patients for the first
transplant versus 1/11 for the second (P < 0Æ001). To
conclude, a short course of rHuEpo therapy before HDT
facilitates the performance of an autologous transplant
without RBC transfusions.
Keywords: autologous stem cell transplantation, tandem
transplantation, myeloma, erythropoietin, recombinant
erythropoietin.
Conventional red blood cell (RBC) transfusions are still
associated with a low risk of a number of serious compli-
cations (Goodnough et al, 1999). It is now well established
that recombinant human erythropoietin (rHuEpo) treat-
ment raises haemoglobin (Hb) levels, reduces the need for
transfusions and improves quality of life in cancer-associ-
ated anaemia (Beguin, 2002). After haematopoietic stem
cell transplantation (HSCT), several trials have administered
very high doses of intravenous (i.v.) rHuEpo starting on d 1
and continuing for either 1–2 months or until erythroid
engraftment. These trials have uniformly shown little (in
allogeneic HSCT) or no (in autologous HSCT) clinical benefit
(Link et al, 1994), with no reduction in transfusion needs
observed. On the other hand, we have shown recently that
rHuEpo was very efficient when started at least 1 month
after an allogeneic transplant, at a time when erythropoietic
marrow recovery is accomplished and endogenous erythro-
poietin (Epo) production is inappropriately low for the
degree of anaemia (Baron et al, 2002a; Baron & Beguin,
2003). However, this approach would not impact on
transfusion requirements when they are most prominent,
i.e. in the first month after transplantation.
Tandem autologous HSCT in first-line therapy has been
shown to be an optimal treatment option for multiple
myeloma (Attal et al, 2002). The aim of this study was to
investigate whether rHuEpo treatment starting 30 d after the
first transplant could increase Hb levels sufficiently to
abrogate the need for RBC transfusion after the second HSCT.
PATIENTS AND METHODS
We developed a protocol of rHuEpo therapy in multiple
myeloma patients in first-line treatment undergoing tandem
autologous peripheral blood stem cell transplantation
(PBSCT), with the aim of avoiding RBC transfusions in the
second HSCT procedure. RhuEpo was not given before the
first transplant, so that patients served as their own internal
controls. Eleven patients, five males and six females, aged
44–64 (median 58) years, were included. The collection and
infusion of PBSC was carried out as described previously
(Andre et al, 2003). The percentage of bone marrow
plasmocytes was 2 ± 4% and 1 ± 1% before the first and
second transplants respectively. Before the first transplant,
polymorphonuclear leucocytes (PMN) and platelet counts
were 2Æ79 ± 1Æ35 and 271 ± 144 · 109/l respectively. The
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conditioning regimen was 200 mg/m2 melphalan for both
transplants. Patients received a mean of 13Æ8 ± 10Æ3 and
15Æ5 ± 10Æ3 CD34+ cells/kg as first and second transplant,
respectively, representing a non-significant difference, and
were treated with granulocyte colony-stimulating factor
(G-CSF) after transplantation. Single-donor platelet transfu-
sions were given if platelet counts decreased below
15 · 109/l. The trigger for RBC transfusions was an Hb
level of 8 g/dl or below.
Patients were scheduled to start subcutaneous (s.c.)
rHuEpo on d 30 ± 3 after the first PBSCT at a dose of
500 U/kg/week (standard dose for cancer anaemia) with
the aim of achieving Hb levels of 13 g/dl. Once that target
was achieved, the dose was reduced, in order to use the
lowest dose capable of maintaining the Hb between 12 and
14 g/dl. As the second HSCT procedure was performed
112 ± 18 d after the first, patients were treated for an
average of 12 weeks. Patients with functional iron defici-
ency (defined by transferrin saturation < 20%) received i.v.
saccharose-iron (Venofer) at a dose of 200 mg/week for
3 weeks.
Complete blood counts, reticulocytes, serum soluble
transferrin receptor (sTfR) (a quantitative measure of total
erythropoietic activity) (R’Zik & Beguin, 2001), serum Epo
and the observed-to-predicted (O/P) ratio were measured as
reported previously (Baron et al, 2002a,b; Beguin et al,
1993).
Unpaired and paired Student’s t-tests were used to
compare biological variables in two groups or to compare
baseline values with later measurements in the same group
of patients. Welsh’s correction was used in cases of unequal
variance. The number of patients requiring transfusions
was compared using Fisher’s exact test.
RESULTS
Efficacy of rHuEpo therapy after the first transplant
The O/P Epo ratio was 0Æ85 ± 0Æ11 on d 30 after the first
PBSCT, showing relative endogenous Epo deficiency. Rhu-
Epo therapy was started on d 31 ± 4. Erythropoiesis, as
assessed by sTfR, increased very quickly from 6577 ±
2539 lg/l at baseline to 10 206 ± 2233 lg/l (P < 0Æ0001)
3 weeks later (Fig 1A). Reticulocytes increased from
66Æ2 ± 25Æ7 · 109/l to 107Æ7 ± 50Æ1 · 109/l during the
same period (P ¼ 0Æ007). The median time to an Hb
increment ‡2 g/dl was 4 weeks, and eight out of 11
patients achieved an Hb of 13 g/dl after a median of
8 weeks. The Hb level increased from 9Æ6 ± 1Æ0 g/dl at
baseline to 13Æ9 ± 1Æ4 g/dl on d 100 (P < 0Æ001). There
was no correlation with the CD34+ cell dose received. In
Fig 1. (A) Change in sTfR between d 0 and d 21 after the start of
rHuEpo therapy. (B) Hb level on d 30 and 100 after PBSCT in
patients treated with rHuEpo (n ¼ 11) or in historical controls
(n ¼ 11). NS, not significant. (C) Hb evolution after the two PBSCT
procedures. (D) RBC transfusions in the two PBSCT procedures.
104 Short Report
 2003 Blackwell Publishing Ltd, British Journal of Haematology 123: 103–105
comparison, in an historical group of 11 transplanted
myeloma patients, Hb increased from 11Æ1 ± 0Æ9 to
11Æ6 ± 1Æ9 g/dl in the same interval (P ¼ 0Æ0042 for
comparison with d 100 Hb in rHuEpo-treated recipients)
(Fig 1B).
Comparison of the two transplant procedures
The Hb level was 9Æ5 ± 1Æ1 g/dl at first transplant versus
12Æ5 ± 0Æ9 g/dl at second transplant. Hb values after the
second transplant remained higher throughout the first
2 weeks but reached identical levels on d 28 (Fig 1C). In
both transplants, erythropoietic activity decreased after the
conditioning regimen, but recovered progressively after d 7.
These findings demonstrate that Hb differences between the
two PBSCT only resulted from higher Hb values achieved
before PBSCT, and not increased erythropoiesis after the
second PBSCT.
Transfusion needs
Ten out of 11 patients required RBC transfusions for the first
PBSCT, versus one out of 11 for the second transplant
(P < 0Æ001) (Fig 1D). RBC and platelet requirements were
1Æ7 ± 1Æ3 and 1Æ0 ± 1Æ1 for the first procedure versus
0Æ1 ± 0Æ3 (P ¼ 0Æ003) and 0Æ5 ± 0Æ7 (NS) for the second
procedure respectively.
DISCUSSION
Our data demonstrate first the remarkable efficacy of
rHuEpo therapy when started 30 d after an autologous
HSCT, when endogenous Epo production becomes inap-
propriately low for the degree of anaemia (Beguin et al,
1998), achieving a normal Hb level on d 100, just before
the second transplant. In addition, our data demonstrate
that the higher Hb levels obtained by rHuEpo therapy
after the first transplant permitted the carrying out of the
second HSCT procedure without RBC transfusions in
> 90% of the patients. Ponchio et al (2000) have reported
previously, in 10 breast cancer patients, that RBC
transfusion requirements can be decreased by rHuEpo
therapy started after PBSC collection. However, in that
study, patients were compared with historical controls,
whereas in our study, patients served as their own
internal controls, receiving exactly the same treatment
schedule with or without rHuEpo before autologous
transplantation. In addition, whereas it was already
known that cancer patients on chemotherapy could
respond to rHuEpo, we show here for the first time that
rHuEpo is at least as efficient when given shortly after
recovery from first autologous HSCT.
In conclusion, in tandem autologous PBSCT for multiple
myeloma, rHuEpo therapy started 30 d after the first PBSCT
permitted performance of the second PBSCT without RBC
transfusion.
ACKNOWLEDGMENT
Frédéric Baron is Research Assistant and Yves Beguin
Research Director of the National Fund for Scientific
Research (FNRS, Belgium). This work was supported in
part by grants from the FNRS.
REFERENCES
Andre, M., Baudoux, E., Bron, D., Canon, J.L., D’Hondt, V., Fassotte,
M.F., D’Hondt, L., Fillet, G., Humblet, Y., Jerusalem, G., Verme-
ulen, P., Symann, M. & Beguin, Y. (2003) Phase III randomized
study comparing 5 or 10 microg per kg per day of filgrastim for
mobilization of peripheral blood progenitor cells with che-
motherapy, followed by intensification and autologous trans-
plantation in patients with nonmyeloid malignancies.
Transfusion, 43, 50–57.
Attal, M., Harousseau, J.L., Facon, T., Guilhot, F. & Doyen, C. (2002)
Double autologous transplantation improves survival of multiple
myeloma patients: final analysis of a prospective randomized study
of the intergroupe francophone du myelome. Blood, 100, 7a.
Baron, F. & Beguin, Y. (2003) Once weekly recombinant human
erythropoietin therapy is very efficient after allogeneic peripheral
blood stem cell transplantation (alloPBSCT) when started soon
after engraftment. Haematologica, 88, 718–720.
Baron, F., Sautois, B., Baudoux, E., Matus, G., Fillet, G. & Beguin, Y.
(2002a) Optimization of recombinant human erythropoietin
therapy after allogeneic hematopoietic stem cell transplantation.
Experimental Hematology, 30, 546–554.
Baron, F., Fillet, G. & Beguin, Y. (2002b) Erythropoiesis after non-
myeloablative stem-cell transplantation is not impaired by
inadequate erythropoietin production as observed after conventional
allogeneic transplantation. Transplantation, 74, 1692–1696.
Beguin, Y. (2002) Prediction of response and other improvements
on the limitations of recombinant human erythropoietin therapy
in anemic cancer patients. Haematologica, 87, 1209–1221.
Beguin, Y., Clemons, G.K., Pootrakul, P. & Fillet, G. (1993) Quan-
titative assessment of erythropoiesis and functional classification
of anemia based on measurements of serum transferrin receptor
and erythropoietin. Blood, 81, 1067–1076.
Beguin, Y., Baron, F. & Fillet, G. (1998) Influence of marrow
activity on serum erythropoietin levels after autologous hema-
topoietic stem cell transplantation. Haematologica, 83, 1076–1081.
Goodnough, L.T., Brecher, M.E., Kanter, M.H. & AuBuchon, J.P.
(1999) Transfusion medicine. First of two parts – blood transfu-
sion. New England Journal of Medicine, 340, 438–447.
Link, H., Boogaerts, M.A., Fauser, A.A., Slavin, S., Reiffers, J., Gorin,
N.C., Carella, A.M., Mandelli, F., Burdach, S. & Ferrant, A. (1994)
A controlled trial of recombinant human erythropoietin after
bone marrow transplantation. Blood, 84, 3327–3335.
Ponchio, L., Zambelli, A., De Stefano, A., Robustelli Della Cuna, F.S.,
Perotti, C. & Pedrazzoli, P. (2000) Transfusion requirement can
be abolished by epoietin-a and autologous platelet predeposit in
patients receiving high dose chemotherapy with stem cell sup-
port. Haematologica, 85, 219–220.
R’Zik, S. & Beguin, Y. (2001) Serum soluble transferrin receptor
concentration is an accurate estimate of the mass of tissue
receptors. Experimental Hematology, 29, 677–685.
Short Report 105
 2003 Blackwell Publishing Ltd, British Journal of Haematology 123: 103–105
